Cooperative Agreement UG3DA064403
Award Date 8/15/25
Completion Date 6/30/27
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10119, USA
Similar Awards
- This federal Project Grant award of $798,828.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The key products and services to be delivered include: The development of an AI platform called M3.AI that will integrate target-based and phenotype-based methodologies to efficiently identify new drug candidates for OUD...
- The National Institute on Drug Abuse (NIDA) awarded a $643,019 Cooperative Agreement to Virginia Commonwealth University (VCU) under the Drug Use and Addiction Research Programs (CFDA 93.279) to explore the potential efficacy and safety of psilocybin as a treatment for cocaine use disorder (COCUD). The project aims to conduct a proof-of-concept randomized controlled trial to evaluate the safety, tolerability, and potential efficacy of psilocybin combined with psychedelic integrative therapy...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- This federal Project Grant award of $139,851 was made by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research on the therapeutic potential of the psychedelic compound psilocybin in treating opioid use disorder (OUD) and post-traumatic stress disorder (PTSD), which are highly comorbid conditions. The project aims to investigate the neurobiological mechanisms by which...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $397,829 Project Grant to Callentis Consulting Group LLC, a woman-owned small business in Austin, Texas. The grant, awarded on May 1, 2025, supports the development of an artificial intelligence (AI) platform to discover new therapeutics for substance use disorders. The key products and services to be delivered include: 1) Curated training datasets and machine learning...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting Mebias Discovery Inc. in the development of a new chemical entity, MEB-1170, for the treatment of opioid use disorder (OUD). The project will complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 as a maintenance medication for OUD, as well as conduct Phase 1 clinical trials to assess the...
- This $399,483 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to generate synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel multivalent compounds for treating substance use disorders (SUDs). The objective is to develop a polypharmacological therapeutic that can restore equilibrium to the opioid, dopaminergic, and serotonergic neurotransmitter...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $3,287,052 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Virogenomics Biodevelopment, Inc., a woman-owned small business in Tigard, Oregon. The award, granted in May 2025, is funding IND-enabling studies and Phase I clinical trials to advance DRHQ, a novel immunotherapeutic compound developed by Virogenomics to treat methamphetamine use disorder. The research...
- The National Institute on Drug Abuse (NIDA) awarded a $164,000 Project Grant to The Trustees of Princeton University for the development of a "Chemical AI and Data Science Platform for the Identification and Discovery of Novel Psychoactive Substances." The 2-year project, running from August 2025 to July 2027, aims to create a comprehensive database of known novel psychoactive substances (NPS) and leverage artificial intelligence (AI) tools to predict the structure and mass...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $306,872 Project Grant to Biomotivate LLC to develop and evaluate the PEACE Platform, a novel solution that leverages personalized audiovisual content and machine learning algorithms to help individuals with opioid use disorders (OUDs) build their capacity to manage negative emotions and stressors. The research design involves integrating generative AI, predictive...